Abstract
Antiplatelet therapy is indicated in hypertensives with manifest cardiovascular disease. The benefit from treatment with low-dose ASA in hypertensive patients without manifest cardiovascular disease is not unequivocal as this strategy is associated with bleeding complications.
Low-dose ASA can be recommended in patients at high total CV risk, particularly in those with decreased renal function.